Teva Pharmaceutical Industries Limited
TEVANYSEHealthcare● Active
$34.71
+$0.52(+1.52%)
Market Cap$40.4B
P/E Ratio—
52W High$37.35
52W Low$14.99
Teva Pharmaceutical Industries Limited (TEVA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TEVA · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $17.26B | $16.54B | $15.85B | $14.93B | $15.88B |
| Cost of Revenue | $8.32B | $8.48B | $8.20B | $7.95B | $8.28B |
| Gross Profit | $8.94B | $8.06B | $7.64B | $6.97B | $7.59B |
| Gross Margin %(computed) | 51.79% | 48.74% | 48.25% | 46.72% | 47.83% |
| Operating Expenses | |||||
| R&D Expenses | $1.01B | $1.05B | $0.95B | $0.84B | $1.09B |
| G&A Expenses | $1.29B | $1.16B | $1.16B | $1.18B | $1.10B |
| Total Operating Expenses | $6.78B | $8.37B | $7.21B | $9.17B | $5.88B |
| Operating Income | $2.16B | ($0.30B) | $0.43B | ($2.20B) | $1.72B |
| Operating Margin %(computed) | 12.50% | -1.83% | 2.73% | -14.72% | 10.81% |
| Interest Income | $0.00B | $0.00B | $0.07B | $0.00B | $0.00B |
| Interest Expense | $0.92B | $0.94B | $1.03B | $0.93B | $0.89B |
| Income Before Tax | $1.24B | ($1.28B) | ($0.62B) | ($3.14B) | $0.67B |
| Income Tax Expense | ($0.18B) | $0.68B | ($0.01B) | ($0.64B) | $0.21B |
| Net Income | $1.41B | ($1.64B) | ($0.56B) | ($2.45B) | $0.42B |
| Net Margin %(computed) | 8.17% | -9.91% | -3.53% | -16.39% | 2.63% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.23 | $-1.45 | $-0.50 | $-2.20 | $0.38 |
| Wtd Avg Shares | 1.15B | 1.13B | 1.12B | 1.11B | 1.10B |
| EBITDA | $3.14B | $4.43B | $1.56B | ($0.93B) | $4.41B |
| EBITDA Margin %(computed) | 18.20% | 26.78% | 9.83% | -6.20% | 27.77% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Teva Pharmaceutical Industries Limited data
About Teva Pharmaceutical Industries Limited (TEVA) Income Statement
Teva Pharmaceutical Industries Limited (TEVA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, TEVA reported revenue of $17.26B, gross profit of $8.94B (gross margin 51.79%), and net income of $1.41B — a net profit margin of 8.17%.
Frequently asked questions
TEVA · 4 questionsTeva Pharmaceutical Industries Limited (TEVA) reported revenue of $17.26B for 2025, up 4.3% year-over-year.
TEVA revenueTEVA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08